Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
Thursday, February 23, 2023AstraZeneca and KYM Biosciences Inci have entered into a global exclusive licence agreement for CMG a potential firstinclass antibody drug conjugate ADC targeting Claudin a promising therapeutic target in gastric cancer Under the licence agreement A...
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor Agonist
Thursday, February 23, 2023Biora Therapeutics Inc the biotech company that is reimagining therapeutic delivery today announced preliminary results from preclinical testing of its PGNOB program reporting an average bioavailability of for semaglutide a GLP receptor agonist Sema...
Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity
Wednesday, February 22, 2023Impel Pharmaceuticals a commercialstage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs today announced that it will implement an operational streamlining plan that will incl...
ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis
Wednesday, February 22, 2023ARS Pharmaceuticals Inc a biopharmaceutical company dedicated to empowering atrisk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis today announced that the company reached agreement t...
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
Wednesday, February 22, 2023Axsome Therapeutics Inc a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system CNS disorders today announced that it has entered into an exclusive license agreement with Pharmanovia to comme...
FDA Accepts Orasis Pharmaceuticals' New Drug Application for CSF-1 for the Treatment of Presbyopia
Tuesday, February 21, 2023Orasis Pharmaceuticals an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people with presbyopia today announced that the US Food and Drug Administration FDA has accepted for review its Ne...
Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
Monday, February 20, 2023Biocytogen Pharmaceuticals Beijing Co Ltd today announced the launch of the Nano Project which aims to develop fully human nanobody drugs for over targets The Project combines Biocytogens proprietary fully human nanobody mouse RenNanoTM with its hi...
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System
Monday, February 20, 2023SciSparc Ltd a specialty clinicalstage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system today announced that its MitoCareX Bio Ltd MitoCareX Bio joint venture which focuses on the disco...
LIfT BioSciences and Minaris Regenerative Medicine Enter into a Development and Manufacturing Partnership for N-LIfT Allogeneic Neutrophil Based Cell Therapy
Thursday, February 16, 2023LIfT BioSciences a pioneering preclinical stage company moving into firstinhuman trials with an allogeneic neutrophil progenitor based cell therapy and Minaris Regenerative Medicine GmbH a leading global contract development and manufacturing service...
Takeda to Present Multiple New Data Analyses at 2023 AAAAI Annual Meeting, Including SPRING Study of TAKHZYRO® (lanadelumab-flyo) in Pediatric Patients With Hereditary Angioedema (HAE)
Wednesday, February 15, 2023Takeda announced it will present seven abstracts related to its hereditary angioedema HAE treatment options at the American Academy of Allergy Asthma Immunology AAAAI Annual Meeting taking place February in San Antonio Texas We are excited to sha...
